Effect of factor XIII on endothelial barrier function

Journal of Experimental Medicine

Volumn 189, Issue 9, 1999, Pages 1373-1382

  Noll, Thomas ^a   Wozniak, Gernold ^a   McCarson, Karin ^a   Hajimohammad, Amir ^a   Metzner, Hubert J ^b   Inserte, Javier ^a   Kummer, Wolfgang ^a   Hehrlein, Friedrich Wilhelm ^a   Piper, Hans Michael ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Centeon Pharma GmbH   (Germany)

Author keywords

Edema; Endothelial permeability; Heart; Ischemia reperfusion; Recombinant human factor XIII

Indexed keywords

BLOOD CLOTTING FACTOR 13;

ANIMAL CELL; AORTA; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; BODY WATER; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FACTOR XIII; MALE; RATS; RATS, WISTAR; STAINING AND LABELING; SWINE;

EID: 0033519359     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.9.1373     Document Type: Article

References (34)

1. Greenberg, C.S., P.J. Birckbichler, and R.H. Rice. 1991. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 5:3071-3077.
2. Muszbek, L., R. Adany, and H. Mikkola. 1996. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit. Rev. Clin. Lab. Sci. 33: 357-421.
3. Polgar, J., V. Hidasi, and L. Muszbek. 1990. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem. J. 267:557-560.
4. Mary, A., K.E. Achyuthan, and C.S. Greenberg. 1988. b-chains prevent the proteolytic inactivation of the a-chains of plasma factor XIII. Biochim. Biophys. Acta. 966:328-335.
5. Knox, P., S. Crooks, and C.S. Rimmer. 1986. Role of fibronectin in the migration of fibroblasts into plasma clots. J. Cell Biol. 102:2318-2323.
6. Paye, M., and C.M. Lapiere. 1986. The lack of attachment of transformed embryonic lung epithelial cells to collagen I is corrected by fibronectin and FXIII. J. Cell Sci. 86:95-107.
7. Ueki, S., J. Takagi, and Y. Saito. 1996. Dual functions of transglutaminase in novel cell adhesion. J. Cell Sci. 109:2727-2735.
8. Barry, E.L., and D.F. Mosher. 1988. Factor XIII cross-linking of fibronectin at cellular matrix assembly sites. J. Biol. Chem. 263:10464-10469.
9. Barry, E.L., and D.F. Mosher. 1989. Factor XIIIa-mediated cross-linking of fibronectin in fibroblast cell layers. Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments. J. Biol. Chem. 264:4179-4185.
10. Lorand, L., M.S. Losowsky, and K.J. Miloszewski. 1980. Human factor XIII: fibrin-stabilizing factor. Prog. Hemost. Thromb. 5:245-290.
11. Board, P.G., M.S. Losowsky, and K.J. Miloszewski. 1993. Factor XIII: inherited and acquired deficiency. Blood Rev. 7:229-242.
12. Keski-Oja, J., D.F. Mosher, and A. Vaheri. 1976. Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell. 9:29-35.
13. Mosher, D.F., and P.E. Schad. 1979. Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. J. Clin. Invest. 64:781-787.
14. Sane, D.C., T.L. Moser, A.M. Pippen, C.J. Parker, K.E. Achyuthan, and C.S. Greenberg. 1988. Vitronectin is a substrate for transglutaminases. Biochem. Biophys. Res. Commun. 157:115-120.
15. Karges, H.E., and R. Clemens. 1988. Factor XIII: enzymatic and clinical aspects. Behring. Inst. Mitt. 82:43-58.
16. Egbring, R., A. Kroniger, and R. Seitz. 1996. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin. Thromb. Hemost. 22:419-425.
17. Kamitsuji, H., K. Tani, M. Yasui, A. Taniguchi, K. Taira, S. Tsukada, Y. Iida, H. Kanki, and H. Fukui. 1987. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schönlein purpura. Efficacy of factor XIII substitution. Eur. J. Pediatr. 146:519-523.
18. Lorenz, R., P. Born, P. Olbert, and M. Classen. 1995. Factor XIII substitution in ulcerative colitis. Lancet. 345:449-450.
19. Lorenz, R., P. Olbert, and P. Born. 1996. Factor XIII in chronic inflammatory bowel diseases. Semin. Thromb. Hemost. 22:451-455.
20. Utani, A., M. Ohta, A. Shinya, S. Ohno, H. Takakuwa, T. Yamamoto, T. Suzaki, and K. Danno. 1991. Successful treatment of adult Henoch-Schönlein purpura with factor XIII concentrate. J. Am. Acad. Dermatol. 24:438-442.
21. Fukui, H., H. Kamitsuji, T. Nagao, K. Yamada, J. Akatsuka, M. Inagaki, S. Shike, Y. Kobayashi, K. Yoshioka, S. Maki, et al. 1989. Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group. Thromb. Res. 56:667-675.
22. Hirahara, K., K. Shinbo, M. Takahashi, and T. Matsuishi. 1993. Suppressive effect of human blood coagulation factor XIII on the vascular permeability induced by anti-guinea pig endothelial cell antiserum in guinea pigs. Thromb. Res. 71: 139-148.
23. Noll, T., A. Hempel, and H.M. Piper. 1996. Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers. Am. J. Physiol. 271:H1878-H1883.
24. Sibelius, U., K. Hattar, A. Schenkel, T. Noll, E. Csernok, W.L. Gross, W.J. Mayet, H.M. Piper, W. Seeger, and F. Grimminger. 1998. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J. Exp. Med. 187:497-503.
25. Albelda, S.M., P.M. Sampson, F.R. Haselton, J.M. McNiff, S.N. Mueller, S.K. Williams, A.P. Fishman, and E.M. Levine. 1988. Permeability characteristics of cultured endothelial cell monolayers. J. Appl. Physiol. 64:308-322.
26. + exchange occurring during anoxia in the genesis of reoxygenation-induced myocardial oedema. J. Mol. Cell. Cardiol. 29:1167-1175.
27. Spahr, R., and H.M. Piper. 1990. Microcarrier cultures of endothelial cells. In Cell Culture Technique in Heart and Vessel Research. H.M. Piper, editor. Springer-Verlag, Berlin. 220-229.
28. Muhs, A., T. Noll, and H.M. Piper. 1997. Vinculin phosphorylation and barrier failure of coronary endothelial monolayers under energy depletion. Am. J. Physiol. 273:H608-H617.
29. Buderus, S., B. Siegmund, R. Spahr, A. Krützfeldt, and H.M. Piper. 1989. Resistance of endothelial cells to anoxia-reoxygenation in isolated guinea pig hearts. Am. J. Physiol. 257:H488-H493.
30. Fickenscher, K., A. Aab, and W. Stuber. 1991. A photometric assay for blood coagulation factor XIII. Thromb. Haemost. 65:535-540.
31. Curtis, C.G., K.L. Brown, R.B. Credo, R.A. Dominak, A. Gray, P. Stenberg, and L. Lorand. 1974. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 13:3774-3780.
32. Karges, H.E., and H.J. Metzner. 1996. Therapeutic factor XIII preparations and perspectives for recombinant factor XIII. Semin. Thromb. Hemost. 22:427-436.
33. Noll, T., A. Muhs, M. Besselmann, H. Watanabe, and H.M. Piper. 1995. Initiation of hyperpermeability in energy-depleted coronary endothelial monolayers. Am. J. Physiol. 268:H1462-H1470.
34. Hempel, A., T. Noll, A. Muhs, and H.M. Piper. 1996. Functional antagonism between cAMP and cGMP on permeability of coronary endothelial monolayers. Am. J. Physiol. 270: H1264-H1271.